Skip to content
DataLookout
Menu

NCT07806058

An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Recruitment opened
    • Start date changed from estimate of Sep 2026 to Oct 15, 2026
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

RDE in advanced pancreatic cancer with RAS mutation or amplification
Timeframe: From the signing of the informed consent form to the end of the safety follow-up. Estimated to be 2 years
Incidence and severity of adverse events (AEs) (per NCI-CTCAE V6.0 criteria)
Timeframe: From the signing of the informed consent form to the end of the safety follow-up. Estimated to be 2 years
ORR assessed by the investigator
Timeframe: From the signing of the informed consent form to the end of the safety follow-up. Estimated to be 2 years

Secondary (7)

Objective Response Rate (ORR) as assessed by the investigator
Disease Control Rate (DCR) as assessed by the investigator
Duration of Response (DoR) as assessed by the investigator
Progression-Free Survival (PFS) as assessed by the investigator
Overall Survival (OS)
Show 2 moreShow less
Anti-Drug Antibodies (ADA)
Incidence and severity of AEs

Arms and interventions

Treatment group A-low dose: HRS-7172 + AG + SHR-1316Experimental
Treatment group A-high dose: HRS-7172 + AG + SHR-1316Experimental
Treatment group A1: HRS-7172 + AGExperimental
Treatment group A2: HRS-7172 + AG + SHR-1316Experimental
Treatment group B-low dose: HRS-717 + HRS-4642+SHR-1316Experimental
Treatment group B-high dose: HRS-717 + HRS-4642+SHR-1316Experimental
Treatment group B1: HRS-717 + HRS-4642Experimental
Treatment group B2: HRS-717 + HRS-4642+SHR-1316Experimental

Drugs: HRS-7172 + AG + SHR-1316, HRS-7172 + AG + SHR-1316;, HRS-7172 + AG;, HRS-717 + HRS-4642+SHR-1316;, HRS-717 + HRS-4642;

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China